Boston Scientific Corporation $BSX Shares Bought by Waycross Partners LLC

Waycross Partners LLC raised its position in shares of Boston Scientific Corporation (NYSE:BSX) by 970.6% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 267,646 shares of the medical equipment provider’s stock after buying an additional 242,646 shares during the period. Boston Scientific makes up about 1.6% of Waycross Partners LLC’s portfolio, making the stock its 27th biggest holding. Waycross Partners LLC’s holdings in Boston Scientific were worth $16,795,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Norges Bank acquired a new position in Boston Scientific during the 4th quarter worth about $2,199,395,000. Assenagon Asset Management S.A. boosted its holdings in Boston Scientific by 133.6% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock valued at $631,135,000 after acquiring an additional 5,751,760 shares during the period. Maverick Capital Ltd. acquired a new position in Boston Scientific in the 4th quarter valued at about $280,735,000. Farallon Capital Management LLC increased its stake in Boston Scientific by 56.7% during the fourth quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock worth $709,362,000 after purchasing an additional 2,693,007 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in Boston Scientific by 31.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 11,035,628 shares of the medical equipment provider’s stock worth $1,052,247,000 after purchasing an additional 2,668,230 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Down 0.2%

NYSE BSX opened at $43.95 on Monday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The stock has a market capitalization of $65.33 billion, a PE ratio of 18.39, a price-to-earnings-growth ratio of 0.84 and a beta of 0.58. The firm has a 50 day moving average of $48.18 and a two-hundred day moving average of $65.66.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue was up 11.6% on a year-over-year basis. During the same period last year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 3.35 EPS for the current fiscal year.

Boston Scientific announced that its board has authorized a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

Several research analysts have recently commented on BSX shares. Citigroup lowered their price objective on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, May 28th. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Jefferies Financial Group reduced their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, June 24th. Leerink Partners decreased their price target on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research report on Thursday, May 28th. Finally, Piper Sandler restated an “overweight” rating and issued a $65.00 price target on shares of Boston Scientific in a research note on Friday, June 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $79.84.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director David C. Habiger acquired 2,250 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 9,800 shares of company stock valued at $554,012 over the last quarter. 0.34% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.